NINDS Cooperative Program in Translational Research Funding Opportunities
Funding for Therapeutics Development Projects
NINDS Exploratory/Developmental Projects in Translational Research for Resistant Epilepsy and Epileptogenesis (R21)- Funding
for pilot projects to generate tools and proof-of-principle for therapeutics development in resistant epilepsy and epileptogenesis.
NINDS Cooperative Program in Translational Research for Resistant Epilepsy and Epileptogenesis (U01)- Funding for full-scale
single component research projects directed at developing new therapies for resistant epilepsy and epileptogenesis.
- NINDS Cooperative Program in Translational Research (U01). The milestone-driven program supports preclinical optimization
and testing of the leads, and projects must be sufficiently advanced that an Investigational New Drug (IND), Investigational
Device Exemption (IDE), 510(k), or 510(k) de novo application to the Food and Drug Administration (FDA) can be submitted during
the project period.
- NINDS Exploratory/Developmental Projects in Translational Research (R21). Funding to support any research activities required
to advance development of candidate therapeutics (drugs, devices, and biologics). Projects can be supported prior to or in
parallel with cooperative agreement funding.
Guidance and Resources for Therapeutics Development Projects
Last updated May 16, 2013